Visfatin, released in maternal milk at different concentrations related to the maternal conditions, could act as a biomarker with a prognostic/predictive value to determine different newborn clinical conditions, particularly the weight loss of the neonate.

The aim of the study is to analyse a retrospective cohort of well characterized mothers in their post-partum period, and to measure Visfatin levels through collection of maternal milk samples. They will be collected in three different moments after the birth (48 hours, 7 days and 30 days) and Visfatin levels will be analysed through an ELISA kit Adipogen. In parallel, the levels of Visfatin will be evaluated in the maternal plasma/serum collected after 1-2 days postpartum.

Lastly, correlations between Visfatin levels and biological/clinical features of mothers and newborns will be explored.

Inclusion Criteria:

• Healthy male and female infants born after 37 weeks' gestation who do not have conditions related to congenital abnormalities
• Maternal hospitalization
• Acquisition of the informed consent form signed by the patient

Exclusion Criteria:

• Refusal of the patient to participate in the study
• Presence of hypogalactia or agalactia in the patient

30 women, hospitalized after childbirth, with respective healthy, breastfed infants